{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-01T23:29:34.333708+00:00","company":{"ticker":"JAZZ","cik":1232524,"company_name":"Jazz Pharmaceuticals plc"},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"executive_change","fact_key":"6da41569bd","cik":1232524,"ticker":"JAZZ","company_name":"Jazz Pharmaceuticals plc","filed_at":"2026-05-29T20:05:00+00:00","payload":{"action":"not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":"2026-05-25","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Anne O'Riordan departed as Director at Jazz Pharmaceuticals plc.","evidence_excerpt":"On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-039147","anchor_url":"https://secwatch.observer/filing/0001628280-26-039147#claim-6da41569bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1232524/000162828026039147/0001628280-26-039147-index.htm"},{"fact_type":"earnings_release","fact_key":"3513953057bb0c3750e66f34eb054643cfb25ec4","cik":1232524,"ticker":"JAZZ","company_name":"Jazz Pharmaceuticals plc","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"$4.43 / $6.34","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter of 2026 (1Q26)","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"$1.1 billion"},"claim":"Jazz Pharmaceuticals plc reported first quarter of 2026 (1Q26) results: revenue $1.1 billion, EPS $4.43 / $6.34. Guidance reaffirmed.","evidence_excerpt":"filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nJazz Pharmaceuticals Announces First Quarter 2026 Financial Results – Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav ® revenues grew 18% YoY with 425 net patient adds – – Epidiolex ®","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001232524-26-000024","anchor_url":"https://secwatch.observer/filing/0001232524-26-000024#claim-3513953057bb0c3750e66f34eb054643cfb25ec4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/0001232524-26-000024-index.htm"},{"fact_type":"executive_change","fact_key":"dc0e99d3f7","cik":1232524,"ticker":"JAZZ","company_name":"Jazz Pharmaceuticals plc","filed_at":"2024-05-31T23:59:59+00:00","payload":{"action":"retiring","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Catherine Sohn departed as Director at Jazz Pharmaceuticals plc.","evidence_excerpt":"On May 31, 2024, Catherine Sohn, Pharm.D. notified the board of directors (the “Board”) of Jazz Pharmaceuticals plc (the “Company”), that she is retiring and will not stand for re-election to the Board, when her term expires, at the Company’s 2024 annual general meeting of shareholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-151941","anchor_url":"https://secwatch.observer/filing/0001193125-24-151941#claim-dc0e99d3f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1232524/000119312524151941/0001193125-24-151941-index.htm"}]}